These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 33934927)
1. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question! Ohashi R; Hartmann A; Martignoni G; Moch H Eur Urol; 2021 Jul; 80(1):e17-e18. PubMed ID: 33934927 [No Abstract] [Full Text] [Related]
2. Reply to Riuko Ohashi, Arndt Hartmann, Holger Moch, and Guido Martignoni's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question! Avulova S; Cheville JC; Lohse CM; Thompson RH; Potretzke AM Eur Urol; 2021 Jul; 80(1):e19. PubMed ID: 33875305 [No Abstract] [Full Text] [Related]
3. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Should Chromophobe Renal Cell Carcinoma Be Graded? Delahunt B; Samaratunga H; Egevad L Eur Urol; 2021 May; 79(5):e141-e142. PubMed ID: 33612375 [No Abstract] [Full Text] [Related]
4. Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31. Should Chromophobe Renal Cell Carcinoma Be Graded? Avulova S; Cheville JC; Lohse CM; Potretzke AM Eur Urol; 2021 May; 79(5):e143-e144. PubMed ID: 33637366 [No Abstract] [Full Text] [Related]
6. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology? Takahashi T Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251 [No Abstract] [Full Text] [Related]
7. Re: Outcomes following partial nephrectomy by tumor size P. L. Crispen, S. A. Boorjian, C. M. Lohse, T. S. Sebo, J. C. Cheville, M. L. Blute and B. C. Leibovich J Urol 2008; 180: 1912-1917. Cimen HI; Serefoglu EC; Balbay MD J Urol; 2009 Sep; 182(3):1232; author reply 1232. PubMed ID: 19625039 [No Abstract] [Full Text] [Related]
8. External validation of a four-tiered grading system for chromophobe renal cell carcinoma. Liu S; Hou M; Yao Y; Mei J; Sun L; Zhang G Clin Exp Med; 2024 Mar; 24(1):61. PubMed ID: 38554222 [TBL] [Abstract][Full Text] [Related]
9. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology? Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750 [No Abstract] [Full Text] [Related]
10. Re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. Re: Umberto Capitanio, Francesco Montorsi. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues. Eur Urol 2011;59:929-30. Brookman-May S; Burger M; Wieland WF; May M Eur Urol; 2011 Nov; 60(5):e45-6; author reply e47. PubMed ID: 21820239 [No Abstract] [Full Text] [Related]
11. Re: outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy: R. H. Breau, P. L. Crispen, R. E. Jimenez, C. M. Lohse, M. L. Blute and B. C. Leibovich J Urol 2010; 183: 903-908. Cimen HI; Canda AE; Balbay MD J Urol; 2010 Nov; 184(5):2212; author reply 2212-3. PubMed ID: 20864129 [No Abstract] [Full Text] [Related]
12. Re: Carlo Bravi, Emily Vertosick, Nicole Benfante, et al. Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol 2019;76:398-403. Kim WH; Yoon HK; Jeong CW Eur Urol; 2020 Jan; 77(1):e14-e15. PubMed ID: 31586511 [No Abstract] [Full Text] [Related]
13. Re: Maxine Sun, Quoc-dien Trinh, Marco Bianchi, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 2012;61:725-31. Sandhu GS; Tanagho YS; Bhayani SB Eur Urol; 2012 Sep; 62(3):e58; author reply e59-60. PubMed ID: 22704368 [No Abstract] [Full Text] [Related]
15. Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661-7 and 2019;75:198. Antonelli A; Minervini A; Capitanio U Eur Urol; 2019 Jul; 76(1):e17-e18. PubMed ID: 30711331 [No Abstract] [Full Text] [Related]
16. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9. Potretzke AM; Larson JA; Bhayani SB Eur Urol; 2015 Feb; 67(2):e19-20. PubMed ID: 25269382 [No Abstract] [Full Text] [Related]
17. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9. Mouracade P Eur Urol; 2015 Oct; 68(4):e82-3. PubMed ID: 26033152 [No Abstract] [Full Text] [Related]
18. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9. Zargar H; Coelho RF; Kaouk JH Eur Urol; 2015 Feb; 67(2):e23. PubMed ID: 25266972 [No Abstract] [Full Text] [Related]
19. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982 [No Abstract] [Full Text] [Related]
20. Re: Hiury S. Andrade, Homayoun Zargar, Peter A. Caputo, et al. Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma. Eur Urol 2016;69:1149-54. Shin TY; Abdel Raheem A; Rha KH Eur Urol; 2016 Oct; 70(4):e100-e101. PubMed ID: 26995331 [No Abstract] [Full Text] [Related] [Next] [New Search]